The medical management of hepatitis C
|
|
- Alberta Simmons
- 5 years ago
- Views:
Transcription
1 CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently, pegylated interferon α (PEG-IFN α) plus ribavirin (RBV) is the standard of care for the treatment of chronic hepatitis C virus (HCV) monoinfection. Evidence from several randomized clinical studies indicates that this combination provides superior virologic efficacy and comparable tolerability to standard IFN α plus RBV regimens in patients coinfected with human immunodeficiency virus (HIV)/HCV. The AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) study is the largest international, randomized, placebocontrolled study to examine the efficacy and safety of combination therapy with PEG-IFN α-2a plus RBV in patients coinfected with HIV/HCV. In the APRICOT study, the overall rate of sustained virologic response among patients treated with PEG- IFN α-2a plus RBV was %, compared to 12% for those patients treated with IFN α-2a plus RBV, considerably higher than reported in other recent trials of this combination in patients coinfected with HIV/HCV. These results indicate that PEG-IFN α-2a plus RBV is superior to standard IFN α-2a plus RBV for treating chronic HCV in patients coinfected with HIV. Pharmacokinetic analysis indicates that RBV had no effect on intracellular levels of lamivudine, stavudine, or zidovudine and does not appear to modify the plasma concentration-time profile of these agents in coinfected patients. (Adv Stud Med. 05;5(4C):S361-S365) *Vice Chair and Chief Medical Officer, Department of Medicine, Mt Sinai School of Medicine, New York, New York. Address correspondence to: Douglas T. Dieterich, MD, Vice Chair and Chief Medical Officer, Department of Medicine, Mt Sinai School of Medicine, 5 East 98th Street, 11th Floor, New York, NY douglas.dieterich@msnyuhealth.org. The medical management of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients presents unique and complex challenges because of high HCV titers, potential drug interactions and toxicities, and the presence of serious liver disease. 1 Over the past few years, several consensus reports have addressed the issue of HCV and HIV coinfection. 2-4 Recent guidelines developed by an international panel of experts recommend that all HIV-positive patients with chronic HCV infection should be considered candidates for HCV therapy, given their higher risk of progression to end-stage liver disease and higher risk of liver toxicity after beginning antiretroviral therapy, as compared with those patients who are HIV negative. 5 Combination treatment with interferon α (IFN α) plus ribavirin (RBV) was the standard therapy for HCV before pegylated interferon α (PEG-IFN α) became available. However, patients coinfected with HIV/HCV who are treated with IFN α plus RBV have lower sustained virologic response (SVR) rates and higher discontinuation rates because of adverse events compared to patients infected with HCV alone. 6,7 The introduction of the combination PEG-IFN α plus RBV allows for more convenient once-weekly dosing, and this combination has superior virologic efficacy in HCV-monoinfected patients compared with standard IFN α plus RBV In an open-label study of PEG-IFN α plus RBV in HIV-coinfected patients, 50% of patients had no detectable HCV RNA at end of treatment and 28% of patients had an SVR. 11 Three randomized controlled trials evaluating PEG-IFN α plus RBV in patients with HIV and HCV infection have now been completed In these studies in patients coinfected with HIV/HCV, PEG-IFN α Advanced Studies in Medicine S361
2 plus RBV had superior virologic efficacy, and discontinuation rates were comparable to those rates for IFN α plus RBV therapy. The AIDS Pegasys Ribavirin International Coinfection Trial (APRICOT) is the largest international, randomized, placebo-controlled study to compare the efficacy and safety of PEG-IFN α-2a plus RBV with that of IFN α plus RBV in patients coinfected with HIV/HCV. 15 In the APRICOT study, the overall SVR rate among patients treated with PEG- IFN α-2a plus RBV was %, considerably higher than rates reported in other recent randomized studies of this combination in patients coinfected with HIV/HCV, compared to 12% for those patients treated with IFN α-2a plus RBV. 15 In contrast to previous randomized studies, the APRICOT study had a 3-arm design to compare the safety and efficacy of PEG-IFN α-2a plus RBV with that of IFN α-2a plus RBV and PEG-IFN α-2a alone. The findings of APRICOT, the interaction between RBV and antiviral agents, and current strategies for the management of chronic HCV infection in HIV-infected patients are discussed in this article. APRICOT STUDY EFFICACY The APRICOT study was conducted at 95 centers in 19 countries between June 00 and September 03. A total of 868 patients were randomly assigned in a 1:1:1 ratio to 48 weeks of treatment with 1 of 3 regimens: subcutaneous IFN α-2a 3 MIU 3 times weekly plus oral RBV 0 mg 2 times/day (total daily dose 800 mg); PEG-IFN α-2a 180 µg weekly plus oral placebo 2 times/day; or PEG-IFN α-2a plus RBV 0 mg 2 times/day (total daily dose 800 mg). 15 The 48-week treatment period was followed by a 24-week observation period. Patients were stratified according to HCV genotype (genotype 1 vs other genotypes), CD4+ cell count (<0/mm 3 vs 0/mm 3 ), HIV treatment (antiretroviral vs no antiretroviral therapy), histologic findings on liver biopsy (cirrhosis vs no cirrhosis), qual- Figure.Virologic Responses at the End of Treatment and at the End of Follow-Up, According to HCV Genotype End of Treatment (wk 48) End of Follow-up (wk 72) IFN α-2a plus ribavirin 100 PEG-IFN α-2a plus placebo 100 PEG-IFN α-2a plus ribavirin Patients with a response, % / / / / / / / / /95 Patients with a sustained response, % /285 58/ / / /175 51/176 18/ / /95 All patients Genotype 1 Genotype 2 or 3 All patients Genotype 1 Genotype 2 or 3 A virologic response was defined as an undetectable HCV-RNA level (<50 IU/mL). The number above each bar indicates the percentage, and the numbers below each bar show the number of patients with a response and the total number in the subgroup. Only patients who received at least 1 dose of study treatment are included in this analysis. P =.008 for the comparison with IFN α-2a plus RBV. P <.001 for the comparisons with IFN α-2a plus RBV and PEG-IFN α-2a plus placebo. HCV = hepatitis c virus; IFN = interferon; PEG-IFN = pegylated interferon. Adapted with permission from Torriani et al. N Engl J Med. 04;351: Copyright 04, Massachusetts Medical Society. All rights reserved. S362 Vol. 5 (4C) April 05
3 ifying alanine aminotransferase quotient (patient s value at baseline divided by the upper limit of normal for the assay), and geographic region. The primary efficacy endpoint was SVR, defined as a serum HCV-RNA level below the limit of detection of the assay (<50 IU/mL) at the end of 24 weeks of follow-up. Of the 868 patients randomized, 860 received study medication: 285 in the group receiving IFN α- 2a plus RBV, 286 in the group receiving PEG-IFN α- 2a plus placebo, and 289 in the group receiving PEG-IFN α-2a plus RBV. 15 Patient demographics were similar to those in previous randomized studies in the coinfected population. The patients were predominantly white males with well-controlled HIV infection and HCV genotype 1. The overall rate of SVR at the end of follow-up was significantly higher among patients treated with PEG-IFN α-2a plus RBV than among those patients treated with IFN α- 2a plus RBV (% vs 12%; odds ratio, 5.; 97.5% confidence interval [CI], ; P <.001) or PEG-IFN α-2a plus placebo (% vs %; odds ratio, 2.89; 97.5% CI, ; P <.001; Figure). 15 The rate of SVR was significantly lower among recipients of IFN α-2a plus RBV than among recipients of PEG-IFN α-2a plus placebo (odds ratio, 0.53; 97.5% CI, ; P =.008). 15 As observed in previous studies in patients coinfected with HIV/HCV, patients infected with HCV genotype 1 had consistently lower rates of SVR than those patients infected with HCV genotype 2 or 3 (Figure). In patients who had an early virologic response by week 12, 30% in the group receiving IFN α-2a plus RBV, 37% in the group receiving PEG-IFN α-2a plus placebo, and 56% in the group receiving PEG- IFN α-2a plus RBV had SVR at week among the treatment groups. However, treatment-related adverse events were more frequent in the 2 groups that received PEG-IFN α-2a (10% PEG-IFN α-2a plus placebo and 8% PEG-IFN α-2a plus RBV vs 5% IFN α-2a plus RBV). 15 Consistent with the findings of previous randomized studies involving patients coinfected with HIV/HCV, the absolute mean CD4+ cell counts decreased uniformly in all 3 groups during treatment, whereas the mean percentage of CD4+ lymphocytes Table 1. Patients Withdrawn From Study Treatment and Adverse Events According to Treatment Group* Interferon Interferon Interferon α-2a α-2a plus Ribavirin α-2a plus Placebo plus Ribavirin Variable (n = 285) (n = 286) (n = 288) Withdrawal from study treatment Number of patients (%) Any reason 111 (39) 90 (31) 72 (25) Adverse events or intercurrent illness 41 (14) 34 (12) 34 (12) Insufficient response 34 (12) 14 (5) 6 (2) Patient s refusal of treatment 18 (6) 9 (3) 12 (4) Laboratory abnormalities 3 (1) 13 (5) 9 (3) Loss to follow-up 12 (4) 12 (4) 7 (2) Other 3 (1) 8 (3) 4 (1) Serious adverse events 44 (15) 59 (21) 50 (17) Treatment-related serious adverse events 15 (5) 28 (10) 24 (8) TOLERABILITY Overall, 39% of patients withdrew from treatment with IFN α-2a plus RBV, 31% with PEG-IFN α-2a plus placebo, and 25% with PEG-IFN α-2a plus RBV (P <.001 for the comparison between IFN α-2a plus RBV and PEG- IFN α-2a plus RBV; Table 1). 15 The most commonly reported side effects were fatigue, fever, and headache, and no difference was observed in the incidence of adverse events *Data on withdrawals and deaths are based on all patients who underwent randomization and received at least 1 dose of study medication. One patient received pegylated interferon (PEG-IFN) α-2a plus ribavirin (RBV), but the patient did not return for a safety assessment. All other analyses included all patients who underwent randomization, received at least 1 dose of study medication, and had at least 1 safety evaluation after baseline. Serious adverse events were defined as fatal or life-threatening events and those events that required or prolonged hospitalization, resulted in persistent or clinically significant disability or congenital anomaly, or required intervention to prevent 1 of the specific serious adverse events listed. P <.001 for the comparison with PEG-IFN α-2a plus RBV by Fisher s exact test. Laboratory abnormalities leading to premature withdrawal from study treatment included anemia, lymphopenia, neutropenia, thrombocytopenia, and increased aminotransferase and creatine kinase levels. In the opinion of the investigator, these events were judged to be possibly or probably related to the study treatment. Adapted with permission from Torriani et al. N Engl J Med. 04;351: Advanced Studies in Medicine S363
4 increased slightly. 15 In the APRICOT study, there was a beneficial PEG-IFN α-associated HIV suppression. Mean HIV-RNA levels decreased by almost a full log for patients who had detectable HIV-RNA at baseline in the groups receiving PEG-IFN α-2a plus placebo or PEG-IFN α-2a plus RBV, whereas mean HIV-RNA levels remained unchanged in patients receiving IFN α plus RBV (Table 2). 15 EFFECT OF ANTIVIRAL AGENTS ON RIBAVIRIN Table 2. Changes in HIV Status According to Treatment Group* Interferon α-2a plus Interferon α-2a plus Interferon α-2a plus Variable Ribavirin (n = 285) Placebo (n = 286) Ribavirin (n = 288) Changes in HIV disease status Number of patients (%) Change in CD4+ count Cells/mm ± 176 (161) -135 ± 173 (176) -157 ± 176 (3) Percentage +1.3 ± 5.9 (123) +1.4 ± 6.3 (135) +3.0 ± 8.2 (160) Change in HIV-1 RNA, log 10 copies/ml All patients ± (163) ± (173) -0.5 ± (4) Patients with detectable ± (56) ± (67) ± (82) HIV-1 RNA at baseline *Values shown are mean (±SD) changes from baseline at 48 weeks, with the number of patients shown in parentheses. Only patients who received 48 weeks of treatment are included. CD4 + percentage indicates percentage of CD4 + lymphocytes. Detectable levels were 50 copies/ml. Adapted with permission from Torriani et al. N Engl J Med. 04;351: The effect of HCV therapy on the treatment of HIV infection is an important area of study. RBV, a guanosine nucleoside analogue, interferes with the intracellular phosphorylation of zidovudine, lamivudine, and stavudine. 16,17 In addition, RBV enhances the phosphorylation of didanosine (ddi) metabolism, increasing drug levels and concomitant toxicities. 18 These toxicities are primarily related to DNA polymerase gamma inhibition, leading to failure of mitochondrial function. RBV should not be used with ddi when treating HCV in HIV-coinfected patients. Another nucleoside or nucleotide analogue should be substituted for ddi in these patients. In a substudy of APRICOT, RBV had no effect on intracellular levels of lamivudine, stavudine, or zidovudine in participants receiving these drugs. RBV did not appear to modify the plasma concentration-time profile of lamivudine, stavudine, or zidovudine. Therefore, RBV does not appear to affect the metabolism of these agents or their corresponding endogenous nucleoside triphosphates. CONCLUSIONS Evidence from recent randomized studies indicates that PEG-IFN α plus RBV is the treatment of choice for patients coinfected with HIV/HCV; it has superior virologic efficacy, and its tolerability is comparable to that of standard IFN α plus RBV. An SVR of % was achieved with PEG-IFN α-2a plus RBV in the APRI- COT study. Overall efficacy in patients coinfected with HIV/HCV appears to be decreased when compared to efficacy in HCV-monoinfected patients, particularly among those patients with HCV genotype 1 infection. This decrease may be caused by the higher HCV viral load in patients coinfected with HIV/HCV. Of particular interest in APRICOT, HCV therapy did not negatively affect the control of HIV infection. Several factors may account for the considerably higher response rates achieved in patients treated with PEG-IFN α-2a plus RBV in the APRICOT study than in other recent randomized clinical trials of PEG- IFN α plus RBV in patients coinfected with HIV/HCV These factors include study design, different type of PEG- IFN α in 2 studies, different dose of RBV, and differences in patient populations. Although the AIDS Clinical Trial Group (ACTG) A5071 and APRICOT studies used equivalent doses of RBV, ACTG A5071 used a doseescalation regimen (starting RBV at 600 mg once daily and increasing to 1000 mg within 12 weeks), whereas the APRICOT study used a fixed 800-mg dose. Although the cumulative dose in the ACTG trial averaged more than 800 mg/day, it was back loaded, leading to speculation that higher rates of SVR may be seen if higher doses could be provided earlier in treatment. Therefore, the timing rather than S364 Vol. 5 (4C) April 05
5 the dose of RBV may have a critical effect on virologic response. In addition to dose and timing of RBV, the use of different types of PEG-IFN α (PEG-IFN α- 2a in ACTG and APRICOT and PEG-IFN α-2b in RIBAVIC) may have had an effect on patient response. Ongoing studies are comparing PEG-IFN α-2a with PEG-IFN α-2b in patients coinfected with HIV/HCV. Liver pathology may also have had an effect on virologic response. In the ACTG A5071 and RIBAVIC trials, liver pathology was more advanced a negative prognostic marker for treatment outcome than it was in the APRICOT study. Serious adverse events, including liver failure, lactic acidosis, or pancreatitis, were highest in the RIBAVIC trial, particularly in patients who were taking ddi before and during use of RBV. Therefore, patients should be switched from ddi-containing regimens before starting PEG-IFN α plus RBV. Data from a substudy of the APRICOT trial showed that RBV had no effect on intracellular levels or metabolism of lamivudine, stavudine, or zidovudine. Therefore, these antiviral agents can be used as part of highly active antiretroviral therapy in patients receiving HCV therapy with PEG-IFN α plus RBV without risk of additional toxicity. The results of APRICOT clearly demonstrate that the combination of PEG-IFN α-2a plus RBV can be an effective and safe treatment for chronic HCV infection in HIV-infected patients. Furthermore, this combination does not appear to have a negative impact on the course of HIV infection. REFERENCES 1. Poles MA, Lew EA, Dieterich DT. Diagnosis and treatment of hepatic disease in patients with HIV. Gastroenterol Clin North Am. 1997;26: Soriano V, García-Samaniego J, Rodríguez-Rosado R, et al. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31(suppl 1): National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. Gastroenterology. 02;123: Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 02; 16: Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 04;18: Landau A, Batisse D, Van Huyen JP, et al. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS. 00;14: Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV/HIV-coinfected subjects: an early report. Gut. 00;47: Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 01;358: Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 02;347: Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 04;1: Perez-Olmeda M, Nunez M, Romero M, et al. IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 03;17: Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 04;351: Carrat F, Bani-Sadr F, Pol S, et al. interferon alfa- 2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 04;292: Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 04;18:F27-F Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 04;351: Fernandez-Larsson R, Patterson JL. Ribavirin is an inhibitor of human immunodeficiency virus reverse transcriptase. Mol Pharmacol. 1990;38: Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987;235: Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 01;357: Advanced Studies in Medicine S365
Over the past decade, the introduction of
MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common
More informationHIV and Hepatitis C Virus Coinfection: Bad Bedfellows
Perspective HIV and Hepatitis C Virus Coinfection: Bad Bedfellows Hepatitis C virus (HCV) infection is common in HIV-infected individuals and is responsible for increasing morbidity in these patients.
More informationAnemia in the Treatment of Hepatitis C Virus Infection
SUPPLEMENT ARTICLE Anemia in the Treatment of Hepatitis C Virus Infection Mark S. Sulkowski Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland Hepatitis C virus (HCV) infection is
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More informationSCIENTIFIC DISCUSSION
London, 26 April 2007 Product name: PegIntron Procedure No: EMEA/H/C/000280/II/0068 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18
More informationTreatment of HCV and HIV coinfection
Annals of Hepatology 2006; 5(Suppl. 1): S42-S48 Annals of Hepatology Treatment of HCV and HIV coinfection J. Alberto Juárez Navarro 1 Chronic infection with hepatitis C virus (HCV) affects 170 million
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationTreatment of HCV in HIV/HCV Coinfection: What Are the New Questions?
Treatment of HCV in HIV/HCV Coinfection: What Are the New Questions? Reprinted from The prn Notebook june 2005 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationLearning Objectives. Disclosures (Activity w/i 12 months) WHY DISCUSS HCV/HIV COINFECTION? HCV/HIV Effect on Health Utilization in A5001
Learning Objectives HCV/HIV COINFECTION Soup to Nuts Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine At the
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationPeginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
original article Alfa-2a plus Ribavirin versus Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons Raymond T. Chung, M.D., Janet Andersen, Sc.D., Paul Volberding, M.D., Gregory K.
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationORIGINAL RESEARCH. Introduction
DOI: 10.1111/ j.1468-1293.2007.00535.x HIV Medicine (2008), 9, 82 88 ORIGINAL RESEARCH r 2008 British HIV Association European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationReviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment
Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationAssessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationAntiviral Therapy 13:
Antiviral Therapy 13:1047 1055 Original article Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV HIV-coinfected patients Cristina
More informationPredictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients
Antiviral Therapy 12:1225 1235 Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients José A Mira 1, Luis F López-Cortés
More informationViral hepatitis and HIV coinfection q
Journal of Hepatology 48 (2008) 353 367 Review Viral hepatitis and HIV coinfection q www.elsevier.com/locate/jhep Mark S. Sulkowski * Johns Hopkins University School of Medicine, 600 rth Wolfe Street,
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationTreatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases
Journal of Viral Hepatitis, 2005, 12, 207 211 doi:10.1111/j.1365-2893.2005.00580.x Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases M. Vogel,
More informationProspective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron
Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron David Finkelman, MD, MBA Janet McRea, LPN Reprint requests to: David
More informationHepatitis C in HIV Patients: The Speeding Sidecar. Andrew Desruisseau, MD,MSCI Assistant Professor Meharry Medical College
Hepatitis C in HIV Patients: The Speeding Sidecar Andrew Desruisseau, MD,MSCI Assistant Professor Meharry Medical College Patient: Mr. DW 40 year old AAM admitted with fever, nonproductive cough and hypoxemia
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationTreatment algorithm for the management of hepatitis C in HIV-coinfected persons
Journal of Hepatology 44 (2006) S49 S55 www.elsevier.com/locate/jhep Treatment algorithm for the management of hepatitis C in HIV-coinfected persons Mark S. Sulkowski* Johns Hopkins Medical Institutions,
More informationManagement of HIV/HCV Coinfection: An Update
Management of HIV/HCV Coinfection: An Update Reprinted from The prn Notebook march 2004 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City by the Physicians Research
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More information2.0 Synopsis. ABT-450/r, ABT-267 M Clinical Study Report R&D/17/0539. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-450, ritonavir, ABT-267, ribavirin, pegylated interferon Name of Active Ingredient: ABT-450, Ritonavir, ABT-267, Ribavirin, Pegylated interferon Individual
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationTreatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationRibavirin (Copegus, Ibavyr, Moderiba)
FACTSHEET Ribavirin (Copegus, Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationTreatment of viral hepatitis in HIV coinfected patients adverse events and their management
Journal of Hepatology 44 (26) S114 S118 www.elsevier.com/locate/jhep Treatment of viral hepatitis in HIV coinfected patients adverse events and their management Stefan Mauss* Center for HIV and Hepatogastroenterology,
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationTreatment of HCV in Persons with HIV Coinfection
Hepatitis C Online PDF created October 2, 2018, 12:45 pm Treatment of HCV in Persons with HIV Coinfection This is a PDF version of the following document: Section 6: Treatment of Key Populations and Unique
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationTherapy of Hepatitis C. Adrian M. Di Bisceglie
Session V Therapy of Hepatitis C Adrian M. Di Bisceglie Saint Louis University Liver Center, St. Louis, Mo. Tremendous progress has been made in developing effective therapies for hepatitis C. The process
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals
HCV RNA profiles among chronic HIV/HCV coinfected individuals in ESPRIT; spontaneous HCV RNA clearance observed in 9 individuals Daniel GRINT 1,2, Ellen TEDALDI 3, Lars PETERS 4, Amanda MOCROFT 1, Brian
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationIntron A HEPATITIS B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.01 Subject: Intron A Hepatitis B Page: 1 of 8 Last Review Date: September 18, 2015 Intron A HEPATITIS
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0144. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationEmerging Approaches for the Treatment of Hepatitis C Virus
Emerging Approaches for the Treatment of Hepatitis C Virus Gap Analysis 1 Physicians may not be sufficiently familiar with the latest guidelines for chronic HCV treatment, including the initiation and
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationNew therapeutic strategies in HBV patients
New therapeutic strategies in HBV patients Philippe HALFON MD, PhD Associate Professor of Medecine Internal Medecine and Infectious Diseases, Hopital Europeen, Marseille, France. NUC + PEG IFN, HBsAg Clearance
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationRibavirin (Ibavyr, Moderiba)
Ribavirin (Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin is taken orally
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More information-HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual
2013: HCV Genome -HCV genome is about 9400 nucleotides long, it is ssrna and positive sense -the 10 viral proteins are first made as a large polyprotein -individual proteins are released from polyprotein
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationOriginal article OPERA: use of pegylated interferon plus ribavirin for treating HCV HIV coinfection in interferon naive patients
Antiviral Therapy 14; 19:735 745 (doi:.3851/imp2757) Original article OPERA: use of pegylated interferon plus ribavirin for treating HCV HIV coinfection in interferon naive patients Giampiero Carosi 1,
More informationPretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy
Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates
More informationAnnals of Hepatology 2003; 2(3): July-September: Original Article
Annals of Hepatology 2003; 2(3): July-September: 135-139 Annals of Hepatology Original Article Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican
More informationWith the advent of highly active antiretroviral therapy
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2010;8:1070 1076 Similar Progression of Fibrosis Between HIV/HCV Infected and HCV Infected Patients: Analysis of Paired Liver Biopsy Samples RICHARD K. STERLING,*,
More informationTechnology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to
More informationABT-493/ABT-530 M Clinical Study Report Post-Treatment Week 12 Primary Data R&D/16/0145. Referring to Part of Dossier: Volume: Page:
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-493/ABT-530 Name of Active Ingredient: ABT-493: (3aR,7S,10S,12R,21E,24aR)- 7-tert-butyl-N-{(1R,2R)-2- (difluoromethyl)-1-[(1- methylcyclopropane-1- sulfonyl)carbamoyl]cyclopropyl}-20,20-
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationProvisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
INVITED ARTICLE HIV/AIDS Kenneth H. Mayer, Section Editor Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons David L. Thomas,
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationAntiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider?
Antiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider? Saturday 22nd March 2014, Mumbai, India Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More information